Exact Sciences Corp (EXAS) has disclosed a new risk, in the Regulation category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exact Sciences Corp faces significant risks due to potential disruptions at the FDA and other regulatory bodies, which could arise from government shutdowns, policy shifts, or funding issues. These disruptions may lead to delays or denials in the approval of new products, adversely affecting the company’s business and financial health. The unpredictability of government funding and political processes further exacerbates these risks, as seen in past and potential future shutdowns. Such events could materially impact the company’s operations by hindering timely regulatory reviews and approvals.
Overall, Wall Street has a Strong Buy consensus rating on EXAS stock based on 18 Buys and 2 Holds.
To learn more about Exact Sciences Corp’s risk factors, click here.